Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study.
Hiroshi MukaeHiroshi YotsuyanagiNorio OhmagariYohei DoiHiroki SakaguchiTakuhiro SonoyamaGenki IchihashiTakao SanakiKeiko BabaYuko TsugeTakeki UeharaPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
Ensitrelvir treatment demonstrated a favorable antiviral efficacy and potential clinical benefit with an acceptable safety profile.